Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2000
11/16/2000CA2373063A1 Death domain containing receptor 4
11/16/2000CA2373039A1 Neuroprotective composition and uses thereof
11/16/2000CA2372815A1 Extracellular matrix and adhesion-associated proteins
11/16/2000CA2372649A1 Methods for lowering viscosity of glucomannan compositions
11/16/2000CA2371219A1 Methods for screening gaba-modulatory compounds for specified pharmacological activities
11/16/2000CA2371095A1 Enhanced delivery of nucleic acid-based drugs
11/16/2000CA2369328A1 Drug delivery device
11/16/2000CA2366201A1 Use of selective antagonists of the .alpha.1b-adrenergic receptor for improvement of sexual dysfunction
11/15/2000EP1051995A2 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
11/15/2000EP1051994A2 5HT1 receptor agonists and a cox-2 inhibitor for the treatment of migraine
11/15/2000EP1051993A2 5HT1 receptor agonists and either a cox-2 inhibitor or NSAID for the treatment of migraine
11/15/2000EP1051977A1 Release-sustaining agent for drugs and sustained-release pharmaceutical composition
11/15/2000EP1051972A1 Nitric oxide donor composition and method for treatment of anal disorders
11/15/2000EP1051655A1 Methods and apparatus for accelerated orthokeratology
11/15/2000EP1051521A2 Method of screening therapeutic agents
11/15/2000EP1051511A1 Methods of identifying modulators of kinases responsive to stress
11/15/2000EP1051500A2 Diagnosis and treatment of aur1 and/or aur2 related disorders
11/15/2000EP1051497A2 Human protein kinase molecules
11/15/2000EP1051490A2 Modulation of cell proliferation, methods and reagents
11/15/2000EP1051488A2 Human growth factor homologs
11/15/2000EP1051486A1 Gtpase derived from human lymph nodes that effects the morphology and cytoskeleton organization of endothelial cells
11/15/2000EP1051479A1 Novel steroid-activated nuclear receptors and uses therefor
11/15/2000EP1051426A1 67 human secreted proteins
11/15/2000EP1051195A1 Identification of agents that protect against inflammatory injury to neurons
11/15/2000EP1051192A2 Methods for the prevention and treatment of fibrosis and sclerosis
11/15/2000EP1051187A1 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
11/15/2000EP1051168A2 Compositions, apparatus and methods for facilitating surgical procedures
11/15/2000EP1051161A1 Method for treating alzheimer's disease
11/15/2000EP1051155A1 Nasal solutions
11/15/2000EP0923378A4 Promotion of wound healing by chemically-modified tetracyclines
11/15/2000EP0717635B1 Methods for regulating gastrointestinal motility
11/15/2000EP0691847B1 Use of aspirin for the manufacture of a medicament for enhancing uterine blood perfusion
11/15/2000CN1273534A Method for treating neurological deficits
11/15/2000CN1058387C Use of asymmetric membranes in delivery devices
11/14/2000US6147109 Treating impotency; brain, cardiovascular, respiratory system and gastrointestinal disorders
11/14/2000US6147108 Administering an effective amount of a gastrointestinal lipase inhibitor, such as, tetrahydrolipstatin
11/14/2000US6147102 Topical aqueous gel suitable for relieving sympathetically maintained peripheral neuropathic pain syndrome
11/14/2000US6147094 Chelating agents and their metal chelates used to reduce cardiotoxic side-effects
11/14/2000US6147081 Ophthalmic solution
11/14/2000US6147072 Administering antidepressant and serotonin reuptake inhibitor
11/14/2000US6147066 Use of antimineralocorticoid compounds against drug withdrawal syndrome
11/14/2000US6147060 Treatment of carcinomas using squalamine in combination with other anti-cancer agents
11/14/2000US6146863 Staphylococcus aureus 3-hydroxyacyl-CoA dehydrogenase
11/14/2000US6146846 Primosome protein a of streptococcus pneumoniae
11/14/2000US6146837 Detecting fc gamma receptor (cd64) in a biological sample by conacting sample with cyanin compound, cy5; illuminating the sample with light of an appropriate excitation wavelength; and detecting fluorescence
11/14/2000US6146831 Cellular models for diabetes and other diseases associated with mitochondrial defects
11/14/2000US6146827 Detecting nucleic acid involved in g protein mediated signal transduction in a t helper cell sample
11/14/2000US6146658 Prodrugs, their preparation and use as pharmaceuticals
11/14/2000US6146645 Uses of oil bodies
11/14/2000US6146636 Substance P antagonists comprising rosaceae plant extracts
11/14/2000US6146622 Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
11/14/2000CA2308826A1 Combination therapy for the treatment of migraine
11/14/2000CA2308824A1 Combination therapy for the treatment of migraine
11/14/2000CA2308323A1 5ht1 receptor agonists and either a cox-2 inhibitor or nsaid for the treatment of migraine
11/14/2000CA2188933C Apolipoprotein e polymorphism and treatment of alzheimer's disease
11/14/2000CA2153775C Potentiation of temozolomide in human tumour cells
11/09/2000WO2000067016A1 Methods for the identification of compounds for the treatment of alzheimer's disease
11/09/2000WO2000066766A1 Optical probes and assays
11/09/2000WO2000066762A2 Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
11/09/2000WO2000066737A1 VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-ALPHA (TNF α) SIGNALING PATHWAY
11/09/2000WO2000066736A1 Growth factor homolog zvegf4
11/09/2000WO2000066722A1 Collection of prokaryotic dna for two hybrid systems helicobacter pylori protein-protein interactions and application thereof
11/09/2000WO2000066713A2 Materials and methods relating to neuronal development
11/09/2000WO2000066708A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
11/09/2000WO2000066630A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS
11/09/2000WO2000066629A1 Modified exendins and exendin agonists
11/09/2000WO2000066618A1 Integrin receptor antagonists
11/09/2000WO2000066617A1 Methods for the treatment of neuronal atrophy-associated dementia
11/09/2000WO2000066572A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
11/09/2000WO2000066566A1 Pyrimidine compounds
11/09/2000WO2000066557A1 New compounds
11/09/2000WO2000066550A1 New compounds
11/09/2000WO2000066225A1 Contraceptive compositions containing cyclic carbamates and amide derivatives
11/09/2000WO2000066182A1 X-ray guided drug delivery
11/09/2000WO2000066175A2 Conjugates as therapies for cancer and prostate diseases
11/09/2000WO2000066173A2 Targeting of infectious agents bearing host cell proteins
11/09/2000WO2000066168A1 Compositions containing benzimidazolones and progestogens
11/09/2000WO2000066167A1 Contraceptive compositions containing indoline derivatives and progestational agents
11/09/2000WO2000066166A1 Contraceptive compositions containing 3,3-substituted indoline derivatives and uses thereof
11/09/2000WO2000066165A1 Contraceptive compositions containing quinazolinone and benzoxazine derivatives
11/09/2000WO2000066164A1 Contraceptive compositions containing antiprogestinic and progestinic
11/09/2000WO2000066163A1 Contraceptive compositions containing 2,1-benzisothiazoline 2,2-dioxides and progestationals
11/09/2000WO2000066161A1 Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy
11/09/2000WO2000066159A1 Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
11/09/2000WO2000066156A1 Death domain containing receptor 5
11/09/2000WO2000066155A1 Methods for preventing reactivation of latent virus and controlling virus replication
11/09/2000WO2000066151A1 Use of heparin-binding antagonists in the inhibition of bradykinin release
11/09/2000WO2000066150A1 New use of a substance in pns
11/09/2000WO2000066142A2 Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
11/09/2000WO2000066141A2 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
11/09/2000WO2000066138A2 Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
11/09/2000WO2000066135A1 Use of phyllanthus for targeted stimulation of the immune system
11/09/2000WO2000066134A1 Use of phyllanthus for treating chronically inflammatory and fibrotic processes
11/09/2000WO2000066123A1 Synergistic combination comprising roflumilast and a pde-3 inhibitor
11/09/2000WO2000066110A1 Glycine cleavage system inhibitors as potential antipsychotics
11/09/2000WO2000066107A2 Antimalarian agents for the treatment of asthma
11/09/2000WO2000066106A2 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
11/09/2000WO2000066103A2 Contraceptive compositions containing cyclic urea and amide derivatives
11/09/2000WO2000066099A2 Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
11/09/2000WO2000066094A2 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents
1 ... 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 ... 1151